Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by PLITheOneon May 20, 2021 8:27am
64 Views
Post# 33236441

Really

Really

As far I know the FDA hasn't approved Ryplasim nor inspected the new plant processing put in place. As far as I am aware this would be very difficult given nobody is at the plant anymore. It's a Ghost town. 

Knowing SALP intent you would quickly understand what the results will be from the FDA. Remember that they want to drive this into the ground and take private!

Ryplasim for $5M, seriously. Why do you think SALP is selling out and all other institutional holders already have? Because they expect approval and revenue? Not!

<< Previous
Bullboard Posts
Next >>